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Background: Cisplatin and many other platinum-based compounds are important anticancer drugs that are used
in treating many cancer types. The development of cisplatin-resistant cancer cells, however, quickly diminishes the
effectiveness of these drugs and causes treatment failure. New strategies that reverse cancer cell drug resistance
phenotype or sensitize cancer cells to these drugs, therefore, need to be explored in order to improve platinum
drug-based cancer treatment. Triptolide is a bioactive ingredient isolated from Tripterygium wilfordii, a Chinese
herbal medicine. Triptolide binds to the TFIIH basal transcription factor and is required for both transcription and
nucleotide excision repair (NER), a DNA repair pathway involved in repairing DNA damage generated by the
platinum-based anticancer drugs.
Methods: Caspase-3 activation and cell growth inhibition assays were used to determine the effect of triptolide on
cisplatin-induced apoptosis and cell growth in lung cancer cells. Real time PCR, immunoblotting, and expression of
reef coral red protein were used to determine a mechanism through which the presence of triptolide increased
cisplatin-induced apoptosis of the lung cancer cells.
Results: Our caspase-3 activation studies demonstrated that the presence of low-levels of triptolide greatly
increased the cisplatin-induced apoptosis of HTB182, A549, CRL5810, and CRL5922 lung cancer cells. The results of
our cell growth inhibition studies revealed that the presence of low-levels triptolide itself had little effect on cell
growth but greatly enhanced cisplatin-induced cell growth inhibition in both A549 and HTB182 cells. The results of
our reef coral-red protein reporter expression studies indicated that the presence of low-levels triptolide did not
affect expression of the reef coral-red protein from pDsRed2-C1 plasmid but greatly inhibited expression of the
reef coral-red protein from cisplatin-damaged pDsRed2-C1 plasmid DNA in A549 cells. In addition, the results of
our protein phosphorylation studies indicated that the presence of low-levels triptolide caused a decrease for
cisplatin-induced CHK1 phosphorylation at Ser317/345 but an increase for cisplatin-induced ATM phosphorylation
at Ser1981 in both HTB182 and A549 cells.
Conclusion: The results of our studies suggest that the presence of low-levels of triptolide potentiates lung
cancer cells to cisplatin treatment by selectively inhibiting NER activity, resulting in an increase in apoptosis of
the lung cancer cells.
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Cisplatin and many other platinum-derived chemical
compounds are important anticancer drugs that have
been used in treating many cancer types, including lung
cancer [1]. The effectiveness of these drugs, however,
often diminishes as cancer cells quickly develop their re-
sistance to the drugs, leading to treatment failure [2].
Novel strategies that can potentiate cancer cells to these
drugs need to be explored in order to improve the ef-
fectiveness of these drugs in cancer treatment.
Platinum-based anticancer drugs, including cisplatin,
execute their anticancer activities mainly by generating
DNA damage (e.g., intra- and inter-strand crosslinks)
and promoting DNA damage-induced cell cycle arrest
and apoptosis [3–6]. However, cancer cells can reduce
or eliminate the cytotoxicity of platinum-based antican-
cer drugs by repairing the platinum DNA damage using
nucleotide excision repair (NER), a DNA repair pathway
that is required for removing DNA damage generated by
many environmental carcinogens and therapeutic drugs
[3]. In addition, cancer cells can also reduce the cytotox-
icity of the platinum-based drugs by altering the mem-
brane permeability to reduce cellular uptake in these
drugs [1, 2]. The effectiveness of platinum-based anti-
cancer treatment would be greatly improved if the NER
activity can be inhibited in cancer cells.
Triptolide is a bioactive ingredient isolated from
Tripterygium wilfordii, a traditional Chinese herbal
medicine [7]. Clinical studies reveal that triptolide pos-
sesses both anti-inflammation and immuno-suppressor
activities [7–9]. Biochemical studies demonstrated that
triptolide binds specifically to XPB, a component of the
TFIIH basal transcription factor, and inhibits its ATPase
activity [10]. Recent studies reveal some anti-tumor ac-
tivities of triptolide [11–13] by promoting a CDK7-
dependent RNA polymerase II (Pol II) degradation and
global transcription inhibition [14]. Triptolide is known
to interfere with a number of transcription factors, in-
cluding p53 [15], NF-κB [16], nuclear factor of activated
T-cells (NFAT) [16], and heat shock factor protein 1
(HSF-1) [17]. The clinical application of triptolide is lim-
ited by its severely adverse side effects, especially at high
concentrations, likely through its global transcription in-
hibition effect. Given the important roles of TFIIH in
both transcription and NER processes, however, it is
possible that triptolide may be used to potentiate cancer
cells to the platinum-based cancer treatment by disrupt-
ing the NER pathway and increasing apoptosis.
In our recent studies, we investigated the effect of
low-levels of triptolide on cisplatin-induced apoptosis of
lung cancer cells. Using A549, HTB182, CRL5810, and
CRL5922 lung cancer cells, results obtained from our
caspase-3 activation studies demonstrated that the pres-
ence of low-levels of triptolide caused a great increase incisplatin-induced caspase-3 activation in these lung can-
cer cells whereas the presence of triptolide or cisplatin
alone had little effect in activating the caspase-3 in these
lung cancer cells. The results of our cell proliferation
studies revealed that the presence of low-levels triptolide
only had moderate or no effect on cell proliferation but
significantly increased cisplatin-induced cell growth in-
hibition in both A549 and HTB182 cells. The results of
our reef coral-red protein expression studies revealed
that the presence of triptolide had little effect on the ex-
pression of reef coral-red protein from pDsRed2-C1
plasmid but great effect on inhibiting the expression of
the reef coral-red protein from cisplatin-damaged
pDsRed2-C1 plasmid in A549 lung cancer cells. In
addition, the results of our protein phosphorylation
studies indicated that the presence of triptolide reduced
cisplatin-induced CHK1 phosphorylation at Ser317/345
but increased cisplatin-induced ATM phosphorylation at
Ser1981 in both A549 and HTB182 lung cancer cells.
These results suggest that the presence of low-levels of
triptolide potentiates lung cancer cells to cisplatin-
induced apoptosis by inhibiting the NER activity, result-
ing in a great increase in apoptosis of these lung cancer
cells.
Results
The presence of low-levels triptolide had little effect
on cell proliferation or gene transcription in A549
and HTB182 lung tumor cells To determine if the
presence of low-levels of triptolide has any effect on cell
growth, we first performed a cell proliferation study.
Both A549 and HTB182 lung tumor cells were seeded
onto 100 mm dishes with the same number of cells. The
cells were either left untreated or treated with 5 ng/ml
and 10 ng/ml triptolide (14nM and 28nM) respectively. At
different time points (0, 24, 48, and 72 h), cell numbers
were counted for both the untreated and triptolide-treated
dishes (Fig. 1a). The results of our cell proliferation studies
revealed that the presence of 5 ng/ml triptolide had little
effect on inhibiting cell proliferation in both HTB182 and
A549 cells; however, the presence of 10 ng/ml has a lim-
ited effect in inhibiting cell proliferation in A549 cells but
great effect in inhibiting cell proliferation of HTB182 cells
(Fig. 1a). Although the mechanism for this inhibition ef-
fect was unknown, it was likely that the global transcrip-
tion inhibition effect of triptolide contributed to this
increased cell proliferation inhibition in HTB182 cells.
To further determine the effect of low-levels of trip-
tolide on gene transcription, we performed a reverse
transcription-based RNA quantification (real time PCR)
study to determine the mRNA level of several genes
involved in DNA repair, DNA methylation, and apop-
tosis, in both untreated and triptolide-treated A549 and
A549 lung cancer cells
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Fig. 1 The effect of triptolide on cell proliferation and gene transcription in both A549 and HTB182 lung tumor cells. For cell growth study, cells
were collected at 24, 48, and 72 h after the triptolide treatment. For gene transcription study, cells treated with triptolide (5 ng/ml for HTB182
and 10 ng/ml for A549 cells) for 20 h and total RNA isolated from the cells were analyzed by real time PCR assay
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real time PCR studies indicated that the presence of
triptolide caused increased transcription in most of the
tested genes. Therefore, no global transcription inhib-
ition effect was detected in these lung tumor cells
treated with low-levels of triptolide. All of our studies,
therefore, were done using 10 ng/ml triptolide for A549
and 5 ng/ml triptolide for HTB182 lung tumor cells.
The presence of low-levels of triptolide resulted in a
great increase of cisplatin-induced caspase-3 activation
in lung tumor cells Although triptolide has been demon-
strated in its anticancer activities [11–13], most of these an-
ticancer activities were observed at relatively high levels of
triptolide presumably through binding to TFIIH andcausing global transcription inhibition. Unfortunately, high
levels of triptolide lead to severely adverse effects, which
limit its potential implication on cancer treatment. Interest-
ingly enough, the TFIIH is also involved in the NER process
[3, 18]. The NER process repairs the cisplatin DNA damage
and eliminates the cytotoxic effect of cisplatin. Therefore, it
is possible that triptolide may be used as a chemo-sensitizer
to potentiate cancer cells to platinum-based cancer treat-
ment by disrupting the NER activity and increasing the
apoptosis event. To explore this possibility, we first deter-
mined the effect of low-levels of triptolide on cisplatin-
induced caspase-3 activation of A549 and HTB182 lung
tumor cells. Both A549 and HTB182 cells were treated with
cisplatin (5 μM) or triptolide (10 ng/ml for A549 and 5 ng/
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Fig. 2 The effect of triptolide on cisplatin-induced caspase-3 activation
in various lung cancer cells. a The effect of triptolide on cisplatin-
induced caspase-3 activation in A549 and HTB182 lung tumor cells.
The cells were treated with triptolide (10 ng/ml for A549 and 5 ng/ml
for HTB182), cisplatin (5 μM), or a combination of both triptolide and
cisplatin (5 μM) for 36 h and caspase-3 activity was determined. b The
effect of triptolide on cisplatin-induced caspase-3 activation in
CRL5810 and CRL5922 lung tumor cells. The cells were treated with
triptolide (1 ng/ml), cisplatin (5 μM), or a combination of both
triptolide (1 ng/ml) and cisplatin (5 μM) for 26 h and caspase-3
activity was determined. The caspase-3 activity was determined using
the Ac-DEVD-AMC as a substrate and measured as nmol AMC/min/mg
protein. The p value <0.01 was considered statistically significant in this
study (*p value < 0.01; **p value < 0.001)
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mined (Fig. 2a). As controls, caspase-3 activity was also de-
termined from the untreated A549 and HTB182 cells
(Fig. 2a). The results of our caspase-3 activation studies re-
vealed that treatment of the A549 and HTB182 cells with
cisplatin or triptolide alone had little effect on activation of
the caspase-3 in these cells (Fig. 2a). When treated withTriptolide 
Cisplatin 
_ _ _ + + 
_ _ _ + + 
A549 
Fig. 3 The effect of triptolide on cisplatin-induced CHK1 phosphorylation a
lung tumor cells. The A549 and HTB182 lung tumor cells were treated with
(5 μM), or a combination of triptolide and cisplatin for 20 h. The cells were
the western blottingboth cisplatin and triptolide, however, a great increase in
caspase-3 activity was observed in both A549 and HTB182
cells (Fig. 2a).
To determine whether the effect of low-dose triptolide in
sensitizing lung cancer cells to cisplatin treatment is limited
to HTB182 and A549 lung tumor cells and if this effect also
exists in other lung tumor cells, we further studied the ef-
fect of low-dose triptolide on cisplatin-induced caspase-3
activation in CRL5810 and CRL5922 lung tumor cells and
a lower-dose triptolide (1 ng/ml) was used in the study
(Fig. 2b). Interestingly, the presence of lower dose triptolide
(1 ng/ml) also was able to potentiate these lung tumor cells
to cisplatin-induced caspase-3 activation in both CRL5810
and CRL5922 lung tumor cells (Fig. 2b).
Together, these results suggested that the presence of
low-level triptolide indeed increased the cisplatin-
induced apoptosis in these lung tumor cells.The presence of low-levels of triptolide caused an
increase of cisplatin-induced ATM phosphorylation
at Ser1981 and a decrease of cisplatin-induced CHK1
phosphorylation at Ser317/345 in both A549 and
HTB182 lung cancer cells To further define a mechan-
ism through which the presence of triptolide causes an
increase of cisplatin-induced caspase-3 activation in
A549 and HTB182 lung cancer cells, we determined the
effect of triptolide on cisplatin-induced CHK1 phosphor-
ylation at Ser317/345 and ATM phosphorylation at Ser1981
(Fig. 3). The CHK1 phosphorylation at Ser317/345 results
in an increased cell survival rate from DNA-damaging
treatment [19–22] whereas the ATM phosphorylation at
Ser1981 indicates the presence of DNA double-stranded
breaks (DSBs) [23]. The results of our protein phosphor-
ylation studies revealed that the presence of triptolide
caused a decrease of cisplatin-induced CHK1 phosphor-
ylation at Ser317/345 and an increase of cisplatin-induced_ + + 






t Ser317/345 and ATM phosphorylation at Ser1981 in A549 and HTB182
triptolide (10 ng/ml for A549 and 5 ng/ml for HTB182), cisplatin
collected and 30 μg of total protein from each cell lysate was used in
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cells (Fig. 3). Therefore, it is likely that inhibiting the CHK1
phosphorylation and increasing the ATM phosphorylation
play important roles in the mechanism through which the
presence of low-levels of triptolide potentiates both A549
and HTB182 lung cancer cells to cisplatin-induced apoptosis.
The presence of low-levels of triptolide inhibited
expression of reef coral red protein from cisplatin-
damaged pDsRed2-C1 plasmid in A549 lung tumor
cells To further define the mechanism through which
the presence of low-level triptolide caused an increase of
cisplatin-induced apoptosis in these lung tumor cells, we
investigated whether the presence of low-level triptolide
inhibited both transcription and the NER process or
only one of these events using A549 lung tumor cells.
The cisplatin-damaged pDsRed2-C1 plasmid DNA was
transfected into A549 cells for DNA repair and expres-
sion of reef coral red protein in the presence or absence
of triptolide. As a positive control, the undamaged
pDsRed2-C1 plasmid was also transfected into A549
cells in a parallel experiment for expression of the reef
coral red protein in the presence or absence of triptolide.
As an internal control, pmaxGFP plasmid DNA, which
carried a CMV promoter-driven green fluorescent pro-
tein (GFP) gene, was co-transfected with pDsRed2-C1
plasmid DNA into A549 lung cancer cells for expression
of the GFP protein in the presence or absence of tripto-
lide. Expressions of both reef coral red and GFP proteinsLive cells  
pmaxGFP/pDsRed2-C1 
pmaxGFP/pDsRed2-C1 
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Fig. 4 The effect of triptolide on reef coral red and GFP proteins expressio
pDsRed2-C1 plasmid (pDsRed2-C1-Cis*) was co-transfected with pmaxGFP
presence or absence of triptolide (10 ng/ml) for 24 h and expressions of bo
microscope using excitation/emission lights with wavelengths of 563 nm/5
proteins. The light image of the same view was also documented for visuawere visualized using fluorescence microscope (Fig. 4).
When undamaged pDsRed2-C1 plasmid was transfected
into A549 lung cancer cells, the reef coral red protein was
highly expressed in the transfected cells with or without
triptolide (Fig. 4f vs 4c). The reef coral red protein was
also highly expressed in the cisplatin-damaged pDsRed2-
C1 plasmid-transfected A549 cells in the absence of trip-
tolide (Fig. 4i). In the presence of triptolide, however,
expression of the reef coral red protein from the cisplatin-
damaged pDsRed2-C1 plasmid was greatly diminished in
A549 cells (Fig. 4l vs 4i). As an internal control, expression
of the GFP protein from pmaxGFP plasmid was not af-
fected by the presence of triptolide, even when expression
of the reef coral red protein from cisplatin-damaged
pDsRed2-C1 plasmid DNA was greatly inhibited in A549
cells by triptolide in the same dish as demonstrated in our
study (Fig. 4k vs 4l). These results suggest that inhibiting
NER process plays an important role in the mechanism
through which the presence of low-level triptolide reduces
reef coral red protein expression from the cisplatin-
damaged pDsRed2-C1 plasmid in A549 lung cancer cells.
Discussion
In these studies, we investigated the effect of low-level
triptolide on cisplatin-induced apoptosis and the
involved mechanism. The results of our caspase-3 acti-
vation studies demonstrated that the presence of low-
levels of triptolide greatly increased cisplatin-induced





ns in A549 lung tumor cells. The undamaged or cisplatin-damaged
plasmid DNA into A549 cells. The transfected cells were cultured in the
th reef coral red and GFP proteins were detected by fluorescence
82 nm and 475 nm/505 nm respectively for reef coral red and GFP
lization of the live cells
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eration studies revealed that the presence of low-levels
of triptolide had little effect on cell proliferation of A549
and HTB182 lung tumor cells. The results of our protein
phosphorylation studies indicated that the presence of
triptolide caused a decrease in cisplatin-induced CHK1
phosphorylation at Ser317/345 and an increase in cisplatin-
induced ATM phosphorylation at Ser1981 in both A549
and HTB182 lung tumor cells. The results of our reef
coral red protein expression studies revealed that the pres-
ence of low-level triptolide only inhibited expression of
the reef coral red protein from the cisplatin-damaged but
not the undamaged pDsRed2-C1 plasmid in A549 lung
tumor cells. All of these results suggest that the presence
of low-levels triptolide potentiates lung cancer cells to
cisplatin treatment by inhibiting NER activity and enhan-
cing cisplatin DNA damage-induced apoptosis.
The results of our caspase-3 activation studies demon-
strated that the presence of low-levels of triptolide
greatly increased the cisplatin-induced apoptosis in
A549 and HTB182 lung tumor cells. The results of our
cell proliferation studies revealed that the presence of
low-levels of triptolide only had a limited effect on cell
proliferation of A549 and HBT 182 lung tumor cells.
Therefore, it is unlikely that this increase in cisplatin-
induced apoptosis is caused by a global transcription in-
hibition effect of triptolide as demonstrated from other
studies [14]. The involving mechanism that causes this
increased apoptosis of the lung cancer cells is unknown.
Since triptolide is known to bind specifically to the XPB
component of TFIIH basal transcription factor and
TFIIH is required for both the transcription and NER
processes, it is possible that inhibiting the NER process
plays an important role in the mechanism through
which the presence of low-level triptolide increases
cisplatin-induced apoptosis in these lung tumor cells.
The results of our reef coral red protein expression stud-
ies also provide very strong evidence to support this
possibility: the presence of low-level triptolide only inhib-
ited expression of reef coral red protein from cisplatin-
damaged but not undamaged pDsRed2-C1 plasmid in
A549 lung tumor cells. However, we cannot rule out a
synergistic effect of both triptolide and cisplatin in this
increased apoptosis. Further studies need to determine if
both mechanisms contribute to the increased apoptosis
or if only one of these mechanisms plays a major role in
this increased apoptosis.
The results of our protein phosphorylation studies re-
vealed that the presence of low-levels of triptolide
caused a decrease in cisplatin-induced CHK1 phosphor-
ylation at Ser317/345. Given the important role of CHK1
in both S- and G2-phase cell cycle arrests and in cell
survival [19–22], it is likely that preventing DNA
damage-caused CHK1 activation contributes to themechanism through which triptolide increases cisplatin-
induced apoptosis of these lung cancer cells. In addition,
the results of our protein phosphorylation studies also
revealed that the presence of triptolide caused a greater
increase in cisplatin-induced ATM phosphorylation at
Ser1981 in HTB182 lung tumor cells. The ATM phos-
phorylation at Ser1981 is caused by DNA double-
stranded breaks (DSBs) [23] and ATM phosphorylation
at Ser1981 causes activation of the ATM signaling path-
way [18, 23]. Activation of the ATM pathway results in
induced expression of important apoptotic proteins,
such as PUMA [24, 25]. Therefore, it is possible that the
presence of triptolide may also increase the cisplatin-
induced apoptosis of A549 and HTB182 lung tumor
cells by inhibiting the NER activity, which increases
DSBs for cisplatin-treated cancer cells and causes activa-
tion of the ATM pathway.
Recent studies have demonstrated the anticancer activ-
ities of triptolide [11–13]. However, most of its antican-
cer activities were observed at high concentrations likely
through inhibiting global transcription [11, 12, 14].
High-levels of triptolide are known to cause severely ad-
verse effects, which reduces its application in cancer
treatment. Our studies focused on testing the possibility
of using low-levels of triptolide to selectively inhibit the
NER activity, and therefore, to potentiate cancer cells to
cisplatin-induced apoptosis while avoiding the adverse
effects caused by high-levels of triptolide. The results of
our studies demonstrated that the presence of low-levels
of triptolide had little effect on cell proliferation or glo-
bal transcription inhibition but had great effect in in-
creasing cisplatin-induced apoptosis in both A549 and
HTB182 lung tumor cells. In addition, the results of our
reef coral red protein expression studies further revealed
that the presence of low-levels of triptolide had little ef-
fect on expression of either reef coral red or GFP pro-
teins from undamaged plasmids but had great effect on
inhibiting expression of reef coral red protein from
cisplatin-damaged pDsRed2-C1 plasmid in the A549
cells. These results suggest that the presence of low-
levels of triptolide only inhibits the NER but not the
transcription process. The mechanism through which
the presence of low-levels of triptolide only selectively
inhibits the NER but not the transcription process is un-
known. One possibility is that two distinguished TFIIH
sub-populations may exist and each has a unique role
rather than playing dual roles in the NER and transcrip-
tion processes. It is likely that these TFIIH may possess
very different sensitivities to triptolide: the TFIIH in-
volved in the NER process has a very high sensitivity to
triptolide and is inhibited by low-levels of triptolide
whereas the TFIIH involved in the transcription process
has a much lower sensitivity to triptolide and is more re-
sistant to triptolide treatment. In fact, some published
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involved in the NER or transcription processes carries
different protein components [26, 27]. It is possible that
the triptolide binding site for the TFIIH involved in the
NER process is more accessible for triptolide than the
TFIIH involved in the transcription process, which
makes the NER process more sensitive to the triptolide
treatment than the transcription process. Alternatively,
it is also possible that triptolide has other protein targets
in addition to TFIIH. Since the effect of triptolide can be
observed at relatively low concentration, it is suggesting
higher affinity interaction between triptolide and its tar-
gets in the cell. Similar to the identification of Heat
Shock Protein 90 (Hsp90) as the actual target of
Geldanamycin, a potent anticancer agent that is cur-
rently under clinical development [28], it is possible to
use reverse pharmacology to identify those possible add-
itional target(s) of this promising anticancer agent by
using triptolide or its analog. The further identification
of the triptolide targeting protein(s) will provide poten-
tial novel targets for the development of more potent
and specific anticancer drugs since triptolide has serious
side effects at higher dose.
The results of our studies clearly demonstrated that
the presence of low-levels of triptolide potentiated the
A549 and HTB182 lung tumor cells to cisplatin-induced
apoptosis. Given the wide application of cisplatin and
other platinum-based drugs in cancer treatment and the
great challenge of cancer cell resistance to platinum-
based chemotherapy, our studies suggest a novel ap-
proach to overcome this cancer cell resistance and to
improve the efficacy of platinum-based cancer treat-
ment. Therefore, knowledge obtained from our studies
will have important clinical relevance in cancer treat-
ment, especially in platinum-based cancer treatment.
However, further studies are needed to determine the
clinical relevance of our studies before applying this
knowledge clinically to cancer treatment.
Several studies have been published which demon-
strate the presence of triptolide increased cisplatin-
induced apoptosis in several cancer types, including
bladder, gastric, liver, ovarian, and pancreatic cancer
[29–34]. The involving mechanisms, however, have not
been determined although some data has suggested the
involvement of p53 [34] and NF-κB pathways [31] in the
process. The results of our studies suggest that inhibiting
the NER activity plays an important role for low-levels
triptolide in increasing cisplatin-induced apoptosis of
lung cancer cells. Therefore, our studies provide an im-
portant mechanism regarding the presence of low-level
triptolide in increasing cisplatin-induced cancer cells
apoptosis. This knowledge would have important impli-
cations on cancer treatment, especially in platinum-
based cancer treatment.Our studies reveal that the presence of low-levels
triptolide can selectively inhibit NER activity without af-
fecting transcription. These results not only suggest trip-
tolide as a NER-specific inhibitor to enhance platinum-
based cancer treatment, but also provide a very useful tool
to study the mechanisms of DNA repair and transcription,
especially the role of TFIIH in DNA repair and transcrip-
tion. Therefore, the knowledge obtained from our studies
not only has its clinical relevance in cancer treatment but
also has its scientific importance in basic research, such as
transcription and DNA repair.
Materials and methods
Cell lines, plasmids, and primers The A549, HTB182,
CRL5810, and CRL5922 lung tumor cells were pur-
chased from the American Type Culture Collection
(ATCC). The A549 lung tumor cells were derived from a
lung carcinoma patient. The HTB182 lung tumor cells
were derived from a lung squamous cell carcinoma pa-
tient. The CRL5810 lung tumor cells were derived from
a stage-2 lung adenocarcinoma patient. The CRL5922
lung tumor cells were derived from a stage 1 lung
adenocarcinoma patient. All the lung tumor cells were
maintained in RPMI1640 medium supplemented with
10 % fetal bovine serum (FBS) at 37 °C with 5 % CO2.
The pDsRed2-C1 plasmid was purchased from Clone-
tech Laboratories, Inc. (Mountain View, CA). The
pmaxGFP plasmid was purchased from Lonza Inc. (Ana-
heim, CA). The pDsRed2-C1 plasmid carried a CMV
promoter-driving reef coral-red protein gene and the
pmaxGFP plasmid carried a CMV promoter-driving
green fluorescence protein (GFP) gene. Both pDsRed2-
C1 and pmaxGFP plasmids were amplified in E. coli
DH10B strain and purified using a QIAGEN Plasmid
MaxiPrep Kit.
The real time PCR primers used in this study were
listed in Table 1 and were synthesized by the Midland
Certified Reagent Company (Midland, TX).
Chemicals Both triptolide (from Tripterygium wilfordii
with a purity ≥98 %) and cisplatin were purchased from
Sigma Aldrich Inc. (St. Louis, MO). The triptolide was
prepared as a 1 mg/ml stock in chloroform and stored
at −80 °C. Cisplatin was prepared freshly in DMSO as a
50 mM solution and used immediately for the study.
Because chloroform has limited solubility in water, the
triptolide treatment was done by carefully adding the
triptolide stock solution to the surface of cell culture
medium and slowly shacking the dish until the solution
completely dissolved into the medium.
Cell proliferation assay Both A549 and HTB182 lung
tumor cells were seeded onto 100 mm dishes at the
Table 1 Primers used in the real time PCR studies
1. Bcl-XL primers:
Bcl-XL forward primer: 5’-GGTGAGTCGGATCGCAGCTTG-3’
Bcl-XL reverse primer: 5’-CTCTCGGCTGCTGCATTGTTC-3’
2. Brca1 primers:
Brca1 forward primer: 5’-CCAGCCTTCTAACAGCTACC-3’
Brca1 reverse primer: 5’-CTGGTAGAACTATCTGCAGAC-3’
3. Dnmt1 primers:
Dnmt1 forward primer: 5’-GAGCAAGTCCGATGGAGAGGC-3’
Dnmt1 reverse primer: 5’-GATGGTGGTTTGCCTGGTGC-3’
4. Dnmt3a Primers:
Dnmt3a forward primer: 5’-GATGAGCGCACAAGAGAGCG-3’
Dnmt3a reverse primer: 5’-CGTCGTACTGGTACGCACACTC-3’
5. Dnmt3b Primers:
Dnmt3b forward primer: 5’-GGTGCGTCGTGCAGGCAGTAG-3’
Dnmt3b reverse primer: 5’-CTCGGCTCTGATCTTCATCC-3’
6. Puma Primers:
PUMA forward primer: 5’-CTCGCTCTCGCTGGCGGAGCAG-3’
PUMA reverse primer: 5’-CGCTGCTGCTCTTGTCTC-3’
7. Xpg Primers:
Xpg forward primers: 5’-GGAAGCTGCTGGAGTGCTCCG-3’
Xpg reverse primers: 5’-TGAGTTCCCATGGCGATCCCG-3’
8. β-Actin Primers:
β-Actin forward primer: 5’-GTACGTTGCTATCCAGGCTGTG-3’
β-Actin reverse primer: 5’-CATGAGGTAGTCAGTCAGGTC-3’
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about 20 % confluence. The cell number was counted
from one dish for both the A549 and HTB182 lung tumor
cells before the triptolide treatment. Some of the dishes
were then treated with triptolide (5 or 10 ng/ml) by care-
fully adding the triptolide stock solution to the surface of
medium and slowly shacking the dishes until the solution
completely dissolved into the medium. The cell number
was counted for both the untreated and triptolide-treated
cells from one dish for both the A549 and HTB182 cells
at 24, 48, and 72 h after the triptolide treatment. The cell
growth curve was generated for both the untreated and
triptolide-treated A549 and HTB182 cells.
Reverse transcription-based RNA quantification
(real time PCR) assay Total RNA was isolated from
both untreated and triptolide-treated A549 (10 ng/ml
triptolide) and HTB182 (5 ng/ml triptolide) cells 20 h
after the treatment. A reverse transcription-based RNA
quantitation (real time PCR) assay was performed to de-
termine the mRNA levels of target genes using both the
High Capacity cDNA Reverse Transcription kit (Applied
Biosystems) and the Sybr Green-based Power PCR sys-
tem (Applied Biosystems) with a StepOne Plus Real timePCR system (ABI). The level of β-actin mRNA was de-
termined for each RNA sample and used as an internal
control for RNA quantification. The mRNA levels of de-
sired target genes in each RNA sample were calculated
as fold changes in comparison to the same gene in the
untreated A549 lung cancer cells.
Caspase-3 activation assay Cells were seeded onto
100 mm culture dishes and incubated at 37 °C over-
night to approximately 30 % confluence. The cells were
treated with triptolide and/or cisplatin at indicated con-
centrations by adding the reagents directly to the cul-
ture medium and incubated at 37 °C incubator for 26 h
(CRL5810 and CRL5922) or 36 h (A549 and HTB182).
The cells were collected and re-suspended in 300 μl in-
sect cell lysis buffer (BD Pharmagen). The cells were
lysed by using sonication for 2 s and then centrifuged
at 4 °C for 10 min. The supernatants were collected
and the caspase-3 activity was measured from each lys-
ate using a protocol described in our previous study
[6, 35].
DNA repair-mediated reef coral-red protein expres-
sion assay The pDsRed2-C1 plasmid DNA was incu-
bated with 10 μM cisplatin in 10 mM Tris (pH8.5) at
37 °C for 6 h to generate cisplatin DNA damage into the
plasmid DNA and then precipitated by 70 % ethanol to
remove free cisplatin. The cisplatin-damaged plasmid
DNA was then dissolved into 10 mM Tris (pH8.5) and
used for the reef coral-red protein expression study. For
transfection, the A549 cells were harvested and re-
suspended in Opti-MEM medium at a density of 4×106
cells/ml. The A549 cells (3×106 cells) were incubated
with both pDsRed2-C1 (4 μg of either undamaged or
cisplatin-damaged plasmid DNA) and pmaxGFP (2 μg)
plasmid DNA at room temperature for 5 min and then
transfected by electroporation in 0.4 cm cuvettes with a
setting of 250v/25 μF. The cells were incubated at room
temperature for 30 min and then seeded onto two
100 mm cell culture dishes. One dish was treated with
triptolide (10 ng/ml) whereas the other dish remained
untreated. The cells were cultured at 37 °C incubation for
24 h and expressions of both reef coral-red and GFP
proteins were visualized by fluorescence microscope using
the excitation/emission light wavelengths of 563 nm/
582 nm and 475 nm/505 nm for reef coral-red and GFP
proteins respectively. The black-white images were also
documented for the same view for visualization of the
cells.
Western blotting assay Cell lystates (20 μg total protein)
prepared from both untreated and treated A549 and
HTB182 lung tumor cells were analyzed by western
blotting to determine the levels of CHK1 phosphorylation
Wang et al. Biomarker Research  (2015) 3:17 Page 9 of 10at Ser317/345 and ATM phosphorylation at Ser1981 using
antibodies that recognized the CHK1 phosphorylation at
Ser317 and Ser345 and ATM phosphorylation at Ser1981
(Cell Signaling). The protein level of tubulin was also de-
termined for the cell lysates as a protein loading control in
the same membrane.
Statistical analysis All data was expressed as the Mean ±
standard deviation (S.D.). Statistical analysis was done using
a GraphPad Prism software (La Jolla, CA). Statistically sig-
nificant differences were determined using a student t-test
with 95 % confidence interval (CI). The data was obtained
from at least three independent experiments.
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